Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.
The efficacy of gamma-hydroxybutyrate (GHB) versus placebo for treating narcolepsy was evaluated in 20 patients with narcolepsy, 10 men and 10 women, using a double-blind counterbalanced crossover design. Each patient completed a daily sleep-wake log and questionnaire during a 14-day baseline, a 29-day placebo period, a 29-day GHB period (50 mg GHB/kg/night given 25 mg/kg h.s. and 25 mg/kg 3 hr later), and a 6-day washout period after each treatment. Cataplexy frequency was significantly lower during GHB treatment than during placebo treatment (p = 0.022). Compared to baseline values, the number of cataplexy attacks per day declined by 52% and 69% during GHB treatment weeks 1 and 4, respectively. The number of subjective arousals from sleep was less with GHB than with placebo (p = 0.035), and the number of sleep attacks was not significantly different during GHB versus placebo treatment. GHB did not have a significant effect on subjective estimates of sleep onset latency, total sleep time, Stanford Sleepiness Scale ratings at morning wake-up, methylphenidate usage, or the number of naps per day. The results indicate that GHB is efficacious for reducing the frequency of cataplexy attacks and subjective nocturnal arousals in patients with narcolepsy within the first 4 weeks of treatment.
Scrima
L
L
Department of Medicine, University of Arkansas for Medical Sciences, Little Rock 72205.
Hartman
P G
PG
Johnson
F H
FH
Hiller
F C
FC
D000293:Adolescent; D000328:Adult; D001143:Arousal / Q000187:drug effects; D002385:Cataplexy / Q000188:drug therapy*; D002940:Circadian Rhythm / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006885:Hydroxybutyrates / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000188:drug therapy*; D011897:Random Allocation; D011930:Reaction Time / Q000187:drug effects; D012895:Sleep, REM / Q000187:drug effects; D012978:Sodium Oxybate / Q000627:therapeutic use*; D014851:Wakefulness / Q000187:drug effects
D006885:Hydroxybutyrates; D012978:Sodium Oxybate